Aug 2, 2023 | Press Release
OVERLAND PARK, Kan.; August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study...
Jun 27, 2023 | Press Release
OVERLAND PARK, Kan.; June 27, 2023 (Business Wire) – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes...
Jan 11, 2023 | Press Release
OVERLAND PARK, KS; January 10, 2023—(BUSINESS WIRE) Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending...
Nov 2, 2022 | Press Release
Study Conducted by Dr. Vince Clinical Research KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and...
Recent Comments